Progenics

ARROW

NCT03939689

Arrow

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PSMA

Investigational

Product

I-131-1095

PSMA-targeted radio ligand therapy

Treatment Arms

o Experimental: I-131-1095 in combination with enzalutamide

o Active Comparator: Enzalutamide